Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyActive Not Recruiting
NCT04873362Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Australia, Austria, Belgium, Brazil +27 more
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsRecruiting
NCT05039619Phase 2Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Lupus Nephritis
United States, Brazil, Canada, France, Italy +7 more
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruiting
NCT05583617Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Multiple Myeloma
Australia, France, Germany, Poland, South Korea +1 more
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaRecruiting
NCT05533775Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Mature B-Cell Non-Hodgkin Lymphoma
United States, Australia, Brazil, China, Czechia +8 more
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)Active Not Recruiting
NCT03824483Phase 2Updated Sep 3, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Leukemia (SLL)
United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruiting
NCT04802759Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
United States, Australia, Israel, South Korea, Spain
A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple SclerosisNot Yet Recruiting
NCT07749157Phase 1Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Relapsing Multiple Sclerosis
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Recruiting
NCT06065748Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
United States, Argentina, Australia, Austria, Belgium +32 more
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Not Yet Recruiting
NCT07503340Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Relapsing-remitting Multiple Sclerosis
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus ErythematosusActive Not Recruiting
NCT05835986Phase 1Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Systemic Lupus Erythematosus
Colombia, France, Germany, Malaysia, Mexico +8 more
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveRecruiting
NCT07413939Phase 2, Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
HER2-positive Breast Cancer
United States, Argentina, Australia, Austria, Belgium +20 more
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerRecruiting
NCT07287150Phase 2Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Metastatic Castration-Resistant Prostate Cancer
United States, Australia, Brazil, Canada, France +7 more
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisActive Not Recruiting
NCT04544449Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Multiple Sclerosis, Primary Progressive
United States, Argentina, Australia, Austria, Brazil +23 more
A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)Recruiting
NCT07531719N/AUpdated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Spinal Muscle Atrophy
Egypt
A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment DecentralizationRecruiting
NCT07527741N/AUpdated Sep 2, 2026
Sponsor: Hoffmann-La Roche
Early-stage HER2+ Breast Cancer
Serbia
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruiting
NCT05862285Phase 3Updated Sep 2, 2026
Sponsor: Hoffmann-La Roche
Cancer
Belgium, Canada, China, Costa Rica, France +10 more
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's DiseaseActive Not Recruiting
NCT07246941Phase 1Updated Sep 2, 2026
Sponsor: Hoffmann-La Roche
Huntington's Disease
Argentina, Australia, Canada, New Zealand, United Kingdom
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology ProductsActive Not Recruiting
NCT05476926N/AUpdated Sep 2, 2026
Sponsor: Hoffmann-La Roche
Neovascular Age-related Macular Degeneration · Diabetic Macular Edema · Retinal Vein Occlusion · Branch Retinal Vein Occlusion
United States, Argentina, Australia, Bulgaria, Canada +24 more
Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)Recruiting
NCT04611867NAUpdated Sep 2, 2026
Sponsor: Inna Chen, MD
Pancreatic Cancer · Lung Cancer, Nonsmall Cell
Denmark
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)Active Not Recruiting
NCT05562947Phase 3Updated Sep 1, 2026
Sponsor: Hoffmann-La Roche
Neovascular Age-related Macular Degeneration · nAMD
China
A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney FunctionsRecruiting
NCT07741604Phase 1Updated Sep 1, 2026
Sponsor: Hoffmann-La Roche
Renal Impairment
United States
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruiting
NCT05646862Phase 3Updated Sep 1, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Australia, Belgium, Brazil +15 more
Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal HemoglobinuriaCompleted
NCT03157635Phase 1, Phase 2Updated Sep 1, 2026
Sponsor: Hoffmann-La Roche
Paroxysmal Hemoglobinuria, Nocturnal
France, Germany, Hungary, Italy, Japan +2 more
Extension Study for the Port Delivery System With Ranibizumab (Portal)Recruiting
NCT03683251Phase 3Updated Aug 31, 2026
Sponsor: Hoffmann-La Roche
Neovascular Age-Related Macular Degeneration
United States, Argentina, Australia, Austria, Belgium +10 more
Biomechanical Precision Medicine Registry for Patients With and Without Heart FailureRecruiting
NCT03480633N/AUpdated Aug 31, 2026
Sponsor: Massachusetts General Hospital
Heart Failure With Normal Ejection Fraction · Heart Failure With Reduced Ejection Fraction · Heart Failure, Right Sided · Heart Failure With Mid Range Ejection Fraction
United States

Previous page Next page